AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JUN 5 - (NewsRx.com & NewsRx.net) -- Swedish biotechnology firm Bioption AB is partnering with the International AIDS Vaccine Initiative (IAVI) to develop and test a new approach for vaccines that can train the immune system to protect against HIV/AIDS.
The vaccines are being built from a technology, Semliki Forest virus (SFV) alphavirus replicons, pioneered by scientists at the Karolinska Institute in Sweden.
The nonprofit IAVI is financing and coordinating the research, with the goal of starting human testing of SFV-based AIDS vaccines within 2 years. Bioption and IAVI have agreed to use their joint ownership of any successful AIDS vaccines to provide them to developing countries rapidly and at reasonable prices.
The Bioption-IAVI team expands the roster of European countries partnering with IAVI to accelerate the development and testing of AIDS vaccines. Scientists and biotechnology companies in the U.K., Germany, and Switzerland are collaborating with IAVI on other AIDS vaccines. The governments of the Netherlands, U.K., Ireland, Denmark, and Norway provide financial support to IAVI.
"The hunt for a safe and effective AIDS vaccine must be a global effort. Europe in particular has a critical leadership role to play in helping end this terrible epidemic," said Seth F. Berkley, MD, president and CEO of IAVI. "We are confident that we can beat back HIV/AIDS with a preventive vaccine, but not without first committing the world's best talent and resources to the cause."
The Bioption-IAVI AIDS vaccines will be constructed from SFV replicons. An SFV replicon is a genetically engineered version of the naturally occurring alphavirus SFV, modified so it does not cause disease, and further modified to include synthetic copies ...